Conversely, a gradual decrease of SOX9 has been related to a progression to advanced stage, high Gleason grade, and metastatic growth in ERG-positive cancers and these effects were strictly limited to the subset of prostate cancers harboring PTEN deletions [28]. This evidence concerns the gene SOX9 and prostate carcinoma.